Hubei Jumpcan Pharmaceutical (600566) H1 2024 earnings summary

Executive summary

• Achieved revenue of ¥4.03 billion in H1 2024, down 12.84% year-over-year due to high base in respiratory products and impact from centralized procurement.

• Net profit attributable to shareholders was ¥1.34 billion, nearly flat year-over-year; adjusted net profit (excluding non-recurring items) declined 5.36%.

• Core products (Pudilan Anti-inflammatory Oral Liquid, Xiao'er Chiqiao Qingre Granules) maintained leading market share, accounting for 56.43% of main business revenue.

• Continued investment in R&D, with new product approvals and clinical progress; increased focus on product pipeline diversification.

• Maintained strong brand and quality reputation, with multiple industry awards and recognitions in 2024.

Financial highlights

• Revenue: ¥4.03 billion, down 12.84% year-over-year.

• Net profit attributable to shareholders: ¥1.34 billion, down 0.11% year-over-year.

• Adjusted net profit (excluding non-recurring items): ¥1.18 billion, down 5.36% year-over-year.

• Operating cash flow: ¥1.57 billion, down 28.71% year-over-year.

• Gross margin: 79.6% (calculated from revenue and cost figures).

• Basic and diluted EPS: ¥1.454, slightly down from ¥1.463 and ¥1.461 in prior year.

Outlook and guidance

• Company will continue to expand product pipeline through internal R&D and external introduction, focusing on OTC channel expansion and cost control.

• Plans to further invest in innovative drug development and clinical research to support long-term growth.

• Will closely monitor policy changes and adjust product and channel strategies to mitigate risks from centralized procurement and industry competition.